title: Sentinel lymph node biopsy in patients with thick primary cutaneous melanoma: patterns of use and underuse utilizing a population-based model.
abstract: Background. Sentinel lymph node biopsy (SLNB) for thick cutaneous melanoma is supported by national guidelines. We report on factors associated with the use and underuse of SLNB for thick primary cutaneous melanoma. Methods. The Surveillance, Epidemiology, and End Results database was queried for patients who underwent surgery for thick primary cutaneous melanoma from 2004 to 2008. We used multivariate logistic regression models to predict use of SLNB. Results. Among 1,981 patients, 833 (41.8%) did not undergo SLNB. Patients with primary melanomas of the arm (OR 2.07, CI 1.56-2.75; P < 0.001), leg (OR 2.40, CI 1.70-3.40; P < 0.001), and trunk (OR 1.82, CI 1.38-2.40; P < 0.001) had an increased likelihood of receiving a SLNB, as did those with desmoplastic histology (OR 1.47, CI 1.11-1.96; P = 0.008). A decreased likelihood of receiving SLNB was noted for advancing age ≥ 60 years (age 60 to 69: OR 0.58, CI 0.33-0.99, P = 0.047; age 70 to 79: OR 0.32, CI 0.19-0.54, P < 0.001; age 80 or more: OR 0.10, CI 0.06-0.16, P < 0.001) and unknown race/ethnicity (OR 0.21, CI 0.07-0.62; P = 0.005). Conclusions. In particular, elderly patients are less likely to receive SLNB. Further research is needed to assess whether use of SLNB in this population is detrimental or beneficial.
authors: Division of Surgical Oncology, Department of Surgery, University of California at Davis, Saeramento, CA 95817, USA ; UC Davis Comprehensive Cancer Center, 4501 X Street, Suite 3010, Sacramento, CA 95817, USA.
authors: Steve R
authors: SR
authors: Martinez
authors: Dhruvil R
authors: DR
authors: Shah
authors: Anthony D
authors: AD
authors: Yang
authors: Robert J
authors: RJ
authors: Canter
authors: Emanual
authors: E
authors: Maverakis
references: J Clin Oncol. 2009 Apr 10;27(11):1857-63
references: 19273706
references: Ann Surg Oncol. 2002 Oct;9(8):754-61
references: 12374658
references: Dermatology. 2011 Feb;222(1):59-66
references: 21196701
references: J Am Acad Dermatol. 1980 Nov;3(5):511-24
references: 7217379
references: In Vivo. 2011 May-Jun;25(3):439-43
references: 21576420
references: World J Surg. 2011 Jul;35(7):1567-72
references: 21559997
references: Cancer. 2009 Dec 15;115(24):5752-60
references: 19827151
references: Curr Opin Oncol. 2006 Mar;18(2):185-8
references: 16462189
references: J Clin Oncol. 2005 Sep 20;23(27):6739-46
references: 16170181
references: Oncology (Williston Park). 1998 Jul;12(7A):153-77
references: 9699216
references: Ann Surg Oncol. 2002 Aug;9(7):637-45
references: 12167577
references: World J Surg. 2009 Nov;33(11):2464-8
references: 19649757
references: J Dtsch Dermatol Ges. 2008 Mar;6(3):198-203
references: 18093216
references: Arch Surg. 1992 Apr;127(4):392-9
references: 1558490
references: World J Surg Oncol. 2011 Apr 14;9:40
references: 21492474
references: Ann Surg Oncol. 2000 Mar;7(2):160-5
references: 10761797
references: J Natl Compr Canc Netw. 2009 Mar;7(3):250-75
references: 19401060
references: J Eur Acad Dermatol Venereol. 2012 May;26(5):560-5
references: 21561487
references: Ann Surg Oncol. 2003 May;10(4):408-15
references: 12734090
references: J Clin Oncol. 2009 Dec 20;27(36):6199-206
references: 19917835
references: Am Surg. 2004 Jan;70(1):59-62
references: 14964550